Episode Details

Today’s guest is Terry J. Rosen, a scientist-entrepreneur who has helped shape the modern era of cancer immunotherapy.

Dr. Rosen is the co-founder and CEO of Arcus Biosciences, a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapies and combination treatments designed to transform outcomes for patients with cancer. Before launching Arcus, he co-founded Flexus Biosciences, which was acquired by Bristol-Myers Squibb in 2015—an early validation of his vision in immune-based therapies.

Across his career, Terry has held senior scientific and leadership roles at major biopharmaceutical organizations including Amgen, Pfizer, and Abbott Laboratories, building a track record that bridges rigorous medicinal chemistry with bold company creation.

In this we discuss:

• Arcus' pipeline and what makes them stand out from other companies in the immuno-oncology field
• What makes Arcus a compelling investment opportunity today and how they balance the long timelines and risks of drug development with the expectations of public markets and investors?

• The key milestones for Arcus in the next year to18 months that the scientific and investment communities should be paying attention to